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Abstract
Widespread use of a live-attenuated influenza vaccine (LAIV) in the United States (licensed as FluMist) raises the possibility that vaccine viruses
will contribute gene segments to the type A influenza virus gene pool. Progeny viruses possessing new genotypes might arise from genetic
reassortment between circulating wild-type (wt) and vaccine strains, but it will be difficult to predict whether they will be viable or exhibit novel
properties. To begin addressing these uncertainties, reverse-genetics was used to generate 34 reassortant viruses derived from wt influenza virus
A/Sydney/5/97 and the corresponding live vaccine strain. The reassortants contained different combinations of vaccine and wt PB2, PB1, PA, NP,M,
and NS gene segments whereas all strains encoded wt HA and NA glycoproteins. The phenotypes of the reassortant strains were compared to wt and
vaccine viruses by evaluating temperature-sensitive (ts) plaque formation and replication attenuation (att) in ferrets following intranasal inoculation.
The results demonstrated that the vaccine virus PB1, PB2, and NP gene segments were dominant when introduced into the wt A/Sydney/5/97 genetic
background, producing recombinant viruses that expressed the ts and att phenotypes. A dominant attenuated phenotype also was evident when
reassortant strains contained the vaccineM or PA gene segments, even though these polypeptides are not temperature-sensitive. Although the vaccine
M and NS gene segments typically are not associated with temperature sensitivity, a number of reassortants containing these vaccine gene segments
did exhibit a more restricted ts phenotype. Overall, no reassortant strains were more virulent than wt, and in fact, 33 of the 34 recombinant viruses
replicated less efficiently in infected ferrets. These results suggest that genetic reassortment between wt and vaccine strains is unlikely to produce
viruses having novel properties that differ substantially from either progenitor, and that the likely outcome of reassortment will be attenuated viruses.
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Influenza viruses are members of the Orthomyxoviridae
family, and as such are enveloped viruses that contain seg-
mented genomes composed of negative-sense, single-stranded
RNA (Wright and Webster, 2001). There are three genera of
influenza viruses (types A, B, and C), which are categorized
based on antigenic differences between the nucleocapsid and
matrix proteins. Type A influenza viruses are grouped further
into subtypes based on the antigenic properties of the viral-
encoded hemagglutinin (HA; subtypes H1 through H16) and
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glycoproteins.
Influenza A and B viruses are important human pathogens
responsible for yearly outbreaks of acute respiratory disease
(Webster et al., 1992; Wright and Webster, 2001). Individuals
can be infected repeatedly with both influenza types, because
the antigenic determinants in the HA and NA glycoproteins
change periodically providing a means by which the viruses can
evade pre-existing humoral immunity. This antigenic variation
is driven by two principal mechanisms. Antigenic drift results
from the relatively frequent accrual of amino acid substitutions
in antigenic determinants caused by nucleotide substitutions
introduced by the error-prone viral RNA-dependent RNA
replicase (Domingo et al., 1997). Antigenic shift results from
the process of genetic reassortment during which entire gene
segments are exchanged between related viruses after a
permissive host is coinfected with multiple strains. Genetic
reassortment plays a key role in emergence of new type A
influenza strains, including pandemic viruses, because a diverse
gene pool exists in infected birds as well as other animals
(Webster et al., 1992).
Live attenuated influenza vaccine (LAIV; FluMist) has been
used in the United States since 2003 (Arvin and Greenberg,
2006; Belshe et al., 2004; Harper et al., 2005). Like traditional
inactivated influenza vaccines (Gerdil, 2003), LAIVis a trivalent
formulation used to vaccinate against two type A strains and one
type B strain (Belshe et al., 2004). For vaccines to account for the
continuous antigenic evolution that occurs in wt viruses,
surveillance data (Stohr, 2003) are studied to identify pre-
dominant circulating strains and subsequently select HA andNA
antigens expected to provide the best vaccine coverage during
the upcoming influenza season. Accordingly, LAIV strains are
prepared in the laboratory by genetic reassortment between wt
isolates, which supply the appropriate HA and NA genes, and
type A or type B master donor viruses (MDV-A or MDV-B) that
contribute the attenuated genetic background into which the wt
glycoprotein genes are introduced (Maassab and Bryant, 1999;
Murphy and Coelingh, 2002).
The attenuated MDV-A genetic background (Maassab, 1967;
Maassab and Bryant, 1999) was derived in the 1960s from the
A/Ann Arbor/6/60 (H2N2) strain following serial passage of the
wt isolate in primary chicken kidney cells cultured at reduced
temperature. Adaptation to these highly specific growth con-
ditions resulted in acquisition of numerous mutations (Cox et
al., 1988; Herlocher et al., 1993, 1996; Murphy and Coelingh,
2002) and outgrowth of a variant (A/Ann Arbor/6/60ca) that
expressed a stable cold-adapted (ca), temperature-sensitive (ts),
and attenuated (att) phenotype. When type Avaccine strains are
produced by reassortment between the MDV-A and a wt isolate,
the subsequent genetic selection and screening procedures result
in isolation of a new virus with a defined genotype composed of
gene segments encoding contemporary wt HA and NA glyco-
proteins and 6 gene segments (PB2, PB1, PA, NP, M and NS)
derived from A/Ann Arbor/6/60ca. Consequently, both the
vaccine and wt viruses encode identical glycoproteins, but the
vaccine strains are genetically and phenotypically distinct
because they encode all the A/Ann Arbor/6/60ca genetic de-terminants that restrict replication in the human host including
those responsible for the ca, ts, and att phenotypes (Table 1).
During periods of influenza A virus activity in a community,
individuals might be exposed to wt virus soon before or soon
after vaccination with LAIV leading to coinfection of the nasal
epithelium. Under these conditions, virus replication and
genetic reassortment might produce progeny that contain
novel genotypes, although it remains difficult to predict whether
strains containing one or more vaccine virus gene segments will
be viable and sufficiently fit to emerge from the general
population of replicating virus, and whether the new strains
might exhibit novel phenotypic properties. To investigate
potential consequences of reassortment between wt and type
A vaccine viruses, reverse-genetics (Fodor et al., 1999;
Neumann et al., 1999) was used to produce 34 recombinant
reassortant strains. These reassortants contained different
combinations of gene segments derived from wt A/Sydney/5/
97 and the corresponding A/Sydney/5/97 vaccine strain.
Consequently, the reassortant strains contained novel gene
constellations not previously tested (Jin et al., 2003, 2004;
Snyder et al., 1988; Subbarao et al., 1992) that were composed
of genes derived from a contemporary wt virus and the much
older and divergent A/Ann Arbor/6/60ca MDV-A genetic
background. Characterization of the recombinant viruses
revealed that none replicated more efficiently or were more
virulent than wt in infected ferrets, and in fact, many of the
reassortant viruses retained properties resembling the attenuated
vaccine strain. Taken together, these results indicated that the
vaccine virus ts and att phenotypic markers were dominant
even when the relevant gene segments were transferred into a
contemporary wt virus genetic background.
Results
Production of recombinant reassortant influenza viruses
Reverse-genetics methodology was used to make a panel of
recombinant viruses that contained different combinations of
gene segments derived from wt A/Sydney/5/97 influenza virus
and the corresponding live vaccine strain. One series of viruses
was engineered by introducing one or more vaccine virus gene
segments into the wt genetic background, and conversely, a
second series was prepared by introducing wt gene segments
into the vaccine virus genetic background.
An exhaustive analysis of all possible genotypes that might
arise from reassortement between two viruses would require
rescue and analysis of 256 recombinant strains (28 potential
combinations). Since it was impractical to produce over 200
recombinants, the experiments were designed to focus primarily
on reassortment of genes encoding components of the viral
ribonucleoprotein (RNP) complex (PB2, PB1, PA, and NP).
This seemed like a reasonable strategy since it was expected that
modification of the viral gene expression and replication
apparatus would lead to phenotypic changes, and because it is
known that these gene segments (Table 1) are key determinants
of vaccine virus phenotype (Cox et al., 1988; Herlocher et al.,
1993, 1996; Jin et al., 2003, 2004; Murphy and Coelingh,
Table 1
Amino acid substitutions that distinguish wt A/Sydney/5/97 from vaccine virus
‡ The data are presented as: Wt residue/amino acid position/vaccine residue.
† Substitutions highlighted in gray distinguish wt A/Ann Arbor/6/60 from A/Ann Arbor/6/60ca (Cox et al., 1988; Herlocher et al., 1993, 1996; Jin et al., 2003, 2004;
Murphy and Coelingh, 2002). Phenotypic properties associated with the vaccine virus substitutions are indicated at the bottom of the table. Two expected codon
substitutions (italicized) were not observed in the vaccine strain; the expected change in PA was K613E and T23N in NP.
* Substitutions that have been shown to contribute to the ts phenotype.
# The MDV-A A/Ann Arbor/6/60ca NS1 protein contains a premature stop codon that truncates the polypeptide by 12 amino acids (KRKMARTARSKV).
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number of reassortants strains in which the M and NS gene
segments were exchanged, because of the importance of NS in
immune evasion (Krug et al., 2003) and the association between
the att phenotype and the vaccine M gene segment (Snyder
et al., 1988; Subbarao et al., 1992).
The study also focused on wt virus A/Sydney/5/97 and the
vaccine strain encoding the identical glycoproteins. Impor-
tantly, wt A/Sydney/5/97 was selected because it consistently
spread to the ferret lung after intranasal inoculation (data not
shown), which facilitated analysis of the att phenotype. It also
was important to compare wt, vaccine, and reassortant viruses
all encoding identical HA and NA, because this ensured that
changes in phenotypic properties would result from reassort-
ment of PB2, PB1, PA, NP, M, or NS, which are the 6 gene
segments responsible for the unique properties of the vaccine
virus vaccine genetic background (Table 1).
Prior to beginning the molecular cloning necessary to rescue
recombinant viruses, the wt and vaccine strains of A/Sydney/5/
97 were subjected to complete genomic sequence analysis(Table 1). Comparison of wt and vaccine virus codons revealed
numerous amino acid coding changes including those pre-
viously associated with the ts, ca, and att phenotypes (shaded in
the table). Although sizable, the number of coding changes
perhaps was predictable because the vaccine virus (A/Ann
Arbor/6/60ca) genetic background was adapted to promote
growth in chick kidney cells and embryonated eggs at reduced
temperature (Maassab and Bryant, 1999), and it was derived
over 30 years ago (Maassab, 1967) providing ample time for
contemporary wt viruses to diverge considerably from this
vaccine progenitor. The divergence in polypeptide coding
sequence also implied that exchange of gene segments between
these two genetic backgrounds would lead to gene constellation
effects [Subbarao et al., 1992 #154], which presumably arise
from suboptimal protein-protein interactions.
The 34 reassortant strains selected for the study (Tables 2 and
3) were viable, and they replicated sufficiently in eggs to
produce virus stocks that could be used for further characteriza-
tion. After the genotypes were confirmed by analysis of
sequence markers present on each gene segment, studies were
Table 2
Temperature sensitivity of recombinant wt A/Sydney/5/97 influenza virus containing vaccine virus gene segment substitutions
a Gene segments are color-coded red (wt) and blue (vaccine). The HA (H3) and NA (N2) gene segments (gray) incorporated in all recombinant strains were
identical. The gene segments were cloned from the H3N2 LAIV virus, which contained wt A/Sydney/5/97 glycoprotein coding sequences.
b Titers were determined three times and reported as an arithmetic mean value.
c Efficiency of plaque formation (EOP): Log10 Titer at 33 °C–Log10 Titer at 39 °C.
d ts is defined as having an EOP ≥2.0; npl, no plaques at 39 °C.
e Limit of detection was 1.7 logs10 PFU per ml.
f The detection limit (1.7 log10 PFU/ml) was used to calculate the EOP for reassortant viruses having no titer at 39 °C.
g Two viruses listed in Tables 2 and 3 are identical, but were analyzed in both series of experiments and are included in both tables for clarity. The reassortant
virus listed above containing 4 vaccine segments (PB2, PB1, PA, NP) is identical to the virus containing wt M and NS in a vaccine virus background (Table 3).
Similarly, the virus listed above containing vaccine virus M and NS gene segments is identical to the vaccine virus in which PB2, PB1, PA, and NP have been
replaced with wt gene segments (Table 3).
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the ts phenotype was assessed by plaque formation on MDCK
cell monolayers at permissive (33 °C) and nonpermissive
(39 °C) temperatures, and the att phenotype was appraised by
quantifying virus replication in the upper and lower respiratory
tract of the ferret.
ts phenotype of recombinant reassortant strains
The ts phenotype is one of the principal attenuating
determinants that limit vaccine virus replication and spread
beyond the upper airways (Murphy and Coelingh, 2002).
Several earlier studies have shown that multiple gene segments
contribute to this property (Table 1) making it a logical pheno-
typic marker by which to monitor the effect of reassortment.
Recombinant viruses were assigned a ts phenotype (Tables 2 and
3) if plaque forming efficiency was reduced by 100-fold or more
(EOP values ≥2) when cells were incubated at nonpermissive
temperature. Replication of the vaccine strain also is sufficientlyimpaired at nonpermissive temperature to result in a no-plaque
(npl) phenotype, and those reassortant strains that exhibited this
most stringent defect were labeled ts and npl.
Table 2 summarizes the results obtained when vaccine virus
gene segments were transferred into the wt genetic background.
Transfer of a single vaccine virus gene was insufficient to
convert wt A/Sydney/5/97 into a temperature-sensitive strain
(reassortant viruses 1–4, 16, and 17). In contrast, when two
vaccine gene segments were transferred (reassortants 5–10 and
18), a number of strains exhibited a ts phenotype. Those
containing vaccine genotypes PB2-PB1, PB2-NP, PB1-NP, or
PA-NP (reassortants 5, 7, 9, and 10) propagated poorly at
nonpermissive temperature, and in the case of the PB2–PB1
genotype (reassortant 5), this resulted in the most restrictive npl
phenotype. The remaining pairs of vaccine gene segments had
little effect on plaque forming efficiency (PB2–PA, PB1–PA, or
M–NS; reassortants 6, 8, 18).
Most recombinant viruses produced after transfer of 3
(reassortants 11–14) or 4 (reassortant 15) vaccine genes into
Table 3
Temperature sensitivity of recombinant vaccine virus containing wt A/Sydney/5/97 gene segment substitutions
a–g See Table 2.
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several also exhibited the npl phenotype (reassortants 11, 12,
and 15) like the vaccine control. It was notable that those strains
exhibiting the npl phenotype all contained both vaccine PB2 and
PB1, which was consistent with the results obtained when just
two vaccine segments were transferred (see virus 5). In agree-
ment with this trend, reassortant strain 13 lacked the vaccine PB1
gene (vaccine genotype PB2–PA–NP) and retained the ability to
produce small plaques at 39 °C. Curiously, a virus containing the
vaccine PB1–PA–NP gene segment combination (reassortant
14) exhibited little defect in plaque forming efficiency at
nonpermissive temperature despite the fact that some reassor-
tants containing just two of these three gene segments (PB1–NP
or PA–NP; reassortants 9 and 10) were temperature-sensitive.
Table 3 summarizes the results produced by transferring
genes in the opposite direction; wt gene segments were
transferred into the vaccine virus genetic background. The
findings revealed that the majority of reassortant viruses were
temperature-sensitive and that 8 exhibited the most restrictive
npl phenotype. All single-gene reassortants remained tempera-
ture-sensitive (reassortants 19–22, 33, and 34) although the wt
PB2 gene segment did relieve the npl phenotype (reassortant
19). Transfer of two wt genes (reassortants 23–28) produced a
range of effects. Three reassortants retained the vaccine ts/npl
phenotype including those that possessed wt genotypes PB2–
PA, PA–NP, or M–NS (reassortants 24, 28, and 15), whereas
three different wt gene pairs (PB2–PB1, PB2–NP, PB1–PA;
reassortants 23, 25, and 26) relieved the npl phenotype. A viruscontaining the wt PB1-NP genotype (reassortant 27) contained
just one remaining gene specifying a ts determinant and did not
exhibit temperature sensitivity. This was consistent with results in
Table 2, which indicated that 2 genes containing ts determinants
were needed to restrict replication. Transfer of 3 or 4 wt genes into
the vaccine background (reassortants 29–32 and 18) did relieve
the ts and npl phenotype in most cases with the one exception
being the reassortant strain containing the wt PB2–PB1–PA
genotype (reassortant 29), which remained temperature sensitive.
Assessment of the att phenotype in infected ferrets
Ferrets are naturally susceptible to infection with human
influenza viruses and serve as an important disease model
(Maassab et al., 1982). Ferrets also serve as the model to assess
the att phenotype (Maassab and Bryant, 1999; Maassab et al.,
1982). Attenuation is measured by the relative ability to
replicate in the lower respiratory tract after intranasal inocula-
tion. Infection with wt viruses generally results in virus
propagation in both the nasal epithelium and the lung, whereas
replication of vaccine strains is restricted to upper airways. The
ts phenotype is thought to be one of the important determinants
responsible for restricting vaccine virus replication to the cooler
upper airways (Murphy and Coelingh, 2002).
When reassortant viruses were tested in ferrets, each
recombinant strain was administered to 4–5 animals from a
larger study group. All study groups also contained ferrets
infected intranasally with control viruses, which included wt
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valid if virus replication in the lung was detected in at least
two-thirds of the ferrets infected with wt virus. This helped
confirm the absence of pre-existing immunity, which was
evaluated in all ferrets by HAI assay prior to the study (see
Materials and methods). Nearly all recombinant viruses were
tested in at least two independent studies (8–10 animals total),
and those few strains that were evaluated in only a single study
(5 animals) were negative for replication in the lung. Viruses
that failed to propagate in the lung like the vaccine control were
assigned the att phenotype.
Table 4 summarizes the results obtained after infection with
reassortant strains produced in the wt A/Sydney/5/97 genetic
background. As expected, all recombinant viruses replicated in
the nasal turbinates, though it was evident that some might have
achieved considerably lower titers, such as those containing theTable 4
Effect of vaccine virus gene segment substitutions on replication of recombinant wt
a Gene segments are color-coded red (wt) and blue (vaccine). The HA (H3) and
identical. The gene segments were cloned from the H3N2 vaccine virus, which co
b Two viruses listed in Tables 4 and 5 are identical. They were included in both
containing 4 vaccine virus gene segments (PB2, PB1, PA, and NP) as well as viru
c Number of animals from which harvested tissue contained virus/total number of
d The average value was calculated (±the standard deviation) from titers obtained
e Number in parenthesis is the percentage of total inoculated animals from which
f NVD, No virus detected (limit of detection was 2.0 Log10 PFU per g tissue).
g Wt control viruses replicated in the lungs of at least 68% of the inoculated a
invasion were labeled wt. Replication of vaccine virus controls was not detected in
replicate in lung of some animals, but fewer than wt.
h Two viruses were assigned the att phenotype despite rare observations of virus
was attributed to genetic reversion.vaccine PB2–PB1 or PB2–PB1–NP genotypes (viruses 5 and
12). Only one reassortant virus was detected in the lung at wt
frequency (virus 17), and all others exhibited reduced capacity
to replicate in the lower respiratory tract. This outcome probably
reflected the fact that all reassortant strains other then virus 17
carried at least one gene segment that possessed a known
attenuating determinant (Table 1). Eight reassortants failed to
replicate in the lung and were assigned the corresponding att
phenotype. These included viruses in which two (PB2–PB1,
PB2–NP, PB1–NP, PA–NP; viruses 5, 7, 9, 10), three (PB2–
PB1–PA, PB2–PB1–NP, PB2–PA–NP; viruses 11–13), or four
(PB2–PB1–PA–NP; virus 15) wt genes were replaced.
Seven reassortant strains listed in Table 4 were designated
att(+/−), because these viruses were detected in the lungs of
some ferrets, but at a frequency considerably lower than wt,
perhaps indicating that these reassortants were partiallyA/Sydney/5/97 in the ferret respiratory tract
NA (N2) gene segments incorporated in all recombinant strains (gray) were
ntained wt A/Sydney/5/97 glycoprotein coding sequences.
series of experiments described in the tables. These include reassortant strains
s containing both vaccine M and NS.
animals inoculated.
from positive tissue samples.
harvested lung tissue contained detectable virus.
nimals. Reassortant strains that attained this level of lower respiratory track
the lung defining the att phenotype. Viruses labeled att(+/−) were observed to
replication in the lung. As described in the text, this breakthrough replication
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gene segment substitution, was found in the lung of just 2 out of
20 animals. Similar findings were obtained with the other
single-gene reassortants (viruses 2–4). Several viruses that
contained multiple vaccine gene segments also fell into the att
(+/−) category (vaccine genotypes PB2–PA, PB1–PA, and
PB1–PA–NP; viruses 6, 8, 14), whichmight have been related to
the fact that none of these strains exhibited a ts phenotype (Table
2).When viruses isolated from lung homogenates were analyzed
by nucleotide sequencing, analysis of attenuation markers
indicated that these strains did not undergo genetic reversion,
but that the breakthrough replication likely was due to a partially
attenuated phenotype. Although second-site suppressor muta-
tions cannot be ruled out completely, these att(+/−) phenotypes
appear to be unique properties resulting from specific gene
constellations.
Virus 18, which contained the vaccine M-NS genotype, and
the recombinant strain that contained just the vaccine M gene
(virus 16), were assigned the att phenotype even though 1 or 2
animals, respectively, seemed to contain low levels of virus in
the lungs (Table 4). Further evaluation of the lung isolates was
not possible because attempts to amplify virus from frozen
lung homogenates failed. Consequently, it could not be de-
finitively determined whether the breakthrough replication in
one or two animals resulted from an incompletely attenuatedTable 5
Effect of wt A/Sydney/5/97 gene segment substitutions on replication of recombina
a–e See Table 4.phenotype or rare instances of genetic reversion. Nevertheless,
the inability to amplify virus from lung tissue supported the
conclusion that these reassortants were highly attenuated like
the vaccine and likely were present at very low levels in the
lung.
When reassortant strains produced in the vaccine virus
genetic background were tested in ferrets, all exhibited the att
phenotype (Table 5). This result demonstrated that the att
phenotype was quite dominant and that it was difficult to reverse
through introduction of wt gene segments. The results also
supported conclusions from earlier studies indicating that
attenuating mutations resided on multiple gene segments (see
Table 1). It was notable as well that there were a number of
reassortant viruses (viruses 18, 27, 30–32 and Table 3) that lost
their ts characteristics yet they remained attenuated.
Comparison of phenotypic traits produced by reassortment
The reassortant viruses were categorized by phenotype in
Table 6 to provide a data summary and a different perspective by
which to compare all of the strains. Group I contains viruses that
exhibited wt traits. There were only two viruses that fit this
description including wt A/Sydney/5/97 and the reassortant
strain that contained the vaccine NS gene in the wt genetic
background (virus 17). The lack of wt-like reassortantsnt vaccine virus in the ferret respiratory tract
Table 6
Summary of reassortant virus phenotypes
a Gene segments is color coded to indicate wt (red) and vaccine (blue) as described in Table 2.
b The definition of the ts, npl, and att phenotypes are described in Tables 2 and 4.
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virus genetic material resulted in weakened strains.
Group II is composed of strains that were non-ts but exhibited
a partially attenuated phenotype. None of these strains contained
the vaccine virus M gene consistent with the conclusion that it
encodes a strongly attenuating determinant (Table 4). Also,
except for virus 14, none of these reassortants contained more
than 1 gene associated with temperature sensitivity. This was
consistent with the conclusion drawn from Table 2, which
indicated that the combined effect of two or more gene segments
containing ts determinants was necessary to render the wt
genetic background temperature-sensitive (also see Table 2).Virus 14, which was the exception, was the unusual recombinant
virus that contained three vaccine virus gene segments including
two that contained ts determinants (vaccine genotype PB1-PA-
NP). Further studies will be necessary to understand why this
gene constellation did not result in temperature sensitivity.
Group III also contained non-ts viruses, but they were fully
attenuated (Table 6). All of these strains contained the vaccine
M gene segment, consistent with the conclusion (Table 4) that it
conferred a dominant att phenotype without conferring evident
temperature sensitivity. Also, none of these recombinants
contained more than one gene associated with temperature
sensitivity reinforcing the implication that two or more were
283C.L. Parks et al. / Virology 367 (2007) 275–287necessary to impart temperature sensitivity on wt/A/Syndey5/
97 background.
Group IV contained viruses that exhibited the ts and att
phenotypes, but did not express the most severe no-plaque
growth restriction associated with vaccine strains. Viruses 7 and
9, which had vaccine genotypes PB2-NP or PB1-NP, respec-
tively, and contained no other known attenuating gene segments
(vaccine PA or M), demonstrated that the ts phenotype ap-
parently was sufficient to attenuate replication in the ferret lung
and that the more restrictive npl phenotype was not absolutely
required. It also was notable that none of the Group IV viruses
contained the vaccine PB2 and PB1 combination. As described
below (see Group V), this supported the conclusion that any
strain containing both vaccine PB2 and PB1 expressed the most
restrictive ts/npl phenotype.
Reassortant strains in Group V resembled the vaccine virus
and expressed the ts/npl/att phenotype. The PB1 and PB2 genes
from the majority of these reassortants were derived from the
vaccine, which seemed to be sufficient to produce a vaccine
virus-like phenotype (see virus 5).Moreover, only two viruses in
Group V did not contain the vaccine PB1-PB2 combination
(viruses 20 and 24). Curiously, both of these strains expressed
the ts/npl phenotype despite their having a composition of ts
markers (PB1–NP or PB2–NP) that might have been expected
to result in expression of temperature-sensitivity but not the most
severe no-plaque defect (see viruses 7 and 9 in Group IV). As
explained in greater detail below, it appears that the vaccine M
gene might enhance expression of the ts phenotype, perhaps
explaining why viruses 20 and 24 exhibited the npl phenotype.
Multiple viruses exhibited properties indicating that the
vaccineM gene or theM-NS combination influenced expression
of the ts phenotype. Table 7 was composed to better illustrate
this phenomenon. For example, the phenotype of virus 4
indicated that the vaccine NP gene by itself was insufficient toTable 7
Effect of vaccine M and NS gene segments on virus phenotype
a,b See Table 6.convert wt A/Sydney into a temperature-sensitive strain, but
when vaccine M and NS are added to the composition (virus
29) the resulting reassortant was rendered temperature-sensitive
even though neither M nor NS encodes a temperature-sensitive
determinant (top of Table 7, viruses 16–18 and Table 1).
Further study will be necessary to determine how M and NS
might contribute to this gene constellation effect.
Finally, it is worth briefly noting that reassortment did seem
to have some effect on replication in the nasal epithelium (Tables
3 and 4) as well. Although there were exceptions to this
generalization, and there can be considerable variation in nasal
turbinate titers, it appeared that wt A/Syndey/5/97 and
reassortants in Group I and II (Table 6) achieved similar titers
in the nasal epithelium, which were about 6 log10 PFU or more
per gram of tissue. Viruses in Groups III-V, including the vaccine
control, generally achieved lower titers that were below 6 log10
PFU per gram. Perhaps this result indicates that viruses
expressing the fully attenuated phenotype also exhibit a more
generalized replication deficit that reduced titers even in the
cooler upper airways.
Discussion
This study was conducted to analyze possible outcomes of
reassortment between circulating wt influenza viruses and the
attenuated strains contained in the live attenuated vaccine.
Recombinant viruses containing different combinations of gene
segments derived from the wt and vaccine strains of A/Sydney/
5/97 influenza virus were produced and their phenotypic
properties were assessed (Tables 2–5, summarized in Table 6).
The analysis principally focused on the phenotypic effect
produced by different combinations of the 4 gene segments
encoding the RNP components (PB2, PB1, PA, and NP), but a
limited number of viruses also were constructed to study the
284 C.L. Parks et al. / Virology 367 (2007) 275–287influence of the M and NS gene segments. All recombinant
strains encoded wt A/Sydney/5/97 HA and NA ensuring that the
phenotypes observed in these studies were not influenced by
changes in the surface glycoproteins and were due to reassort-
ment of the unique genetic content that can be supplied by the
vaccine virus genetic background. Overall, the results revealed
that virtually any of the 6 gene segments donated to a reassortant
strain by the vaccine virus genetic background produced de-
tectable growth restriction (Tables 2–6). Perhaps, only exchange
of the NS gene segment proved to be neutral (Table 6). Clearly,
none of the reassortant viruses appeared to be more virulent than
wt A/Sydney/5/97 in infected ferrets, and in fact, 33 of the 34
recombinant strains exhibited some level of attenuation (Tables
4 and 5). These data indicate that natural reassortment between
wt type A influenza virus and vaccine strains will lead pre-
dominantly to weakened progeny. To generalize this conclusion,
additional studies will be necessary that might examine gene
segment combinations not tested here or evaluate the effect of
using different wt genetic backgrounds.
It also should be noted that this work did not address potential
consequences of glycoprotein gene reassortment. The decision
to use identical wt HA and NA gene segments in all re-
combinants seemed reasonable, given that the impetus for
conducting this study was to examine how the outcome of
reassortment might be affected by the unique genetic content
supplied by vaccine viruses. It is also worth emphasizing that the
glycoproteins encoded by vaccine viruses are not unique since
they originate from circulating field isolates; accordingly, the
live vaccines are not expected to donate novel HA or NA gene
segments to a reassortant strain.
Conclusions drawn from evaluation of vaccine and wt A/
Sydney/5/97 reassortants agreed with earlier results identifying
PB2, PB1, and NP as key determinants of the ts phenotype. In
some of the earlier studies, the data indicated that transfer of
vaccine PB2 or PB1 (Jin et al., 2004; Snyder et al., 1988) was
sufficient to impart the ts phenotype on a non-ts genetic
background. Results in Tables 2 and 3 also demonstrated that
expression of the ts and ts/npl phenotypes correlated with
reassortment of the PB1 or PB2 gene segments, but that this
effect was only evident when 2 or more vaccine virus gene
segments were transferred into the wt A/Sydney/5/97 genetic
background. This might be best illustrated in Table 2 where
transfer of the vaccine PB1 or PB2 into the wt A/Sydney/5/97
background (viruses 1 and 2) failed to produce a ts or ts/npl
phenotype, whereas transfer of certain pairs of vaccine gene
segments (PB2–PB1, PB2–NP, or PB1–NP; viruses 5, 7 and 9)
resulted in temperature sensitivity. Similarly, the NP gene
contribution to the ts phenotype was notable only in combination
with other vaccine virus-derived genes (Table 2, PB2–NP, PB1–
NP, or PA–NP; viruses 7, 9, and 10) in agreement with results
reported previously (Jin et al., 2003). Taken together, these data
consistently identify PB2, PB1, and NP as key determinants of
the ts phenotype, but also indicate that the genetic background
used for the analysis significantly influences the expression of
this phenotypic trait.
Previous reports have indicated that attenuating mutations
reside on 5 different gene segments (PB2, PB1, PA, NP, M) inthe A/Ann Arbor/6/60ca vaccine virus background (Table 1).
The results presented in Tables 4 and 5 provide rather striking
support for this conclusion. Transfer of any one of these vaccine
gene segments into the wt A/Sydney/5/97 genetic background
diminished its ability to replicate in the lungs (Table 4), though
single-gene reassortment was not sufficient to completely pre-
vent lower respiratory infection in all cases. In most instances,
transfer of two vaccine virus genes (Table 4; PB2–PB1, PB2–
NP, PB1–NP, PA–NP, M–NS) was adequate to produce the
full att phenotype. Consistent with the rather dominant effect
of the vaccine genes, it proved to be very difficult to reverse
the att phenotype of the vaccine virus by replacing gene
segments with those from wt A/Sydney/5/97. In fact, of the
18 recombinant viruses prepared in the vaccine virus genetic
background (Table 5), none was capable of replicating in the
ferret lung.
It was evident that the presence of the vaccine M and NS
genes increased the temperature sensitivity of some viruses
(Table 7). Additional studies will be necessary to determine
whether this effect required the vaccine M, NS, or both genes. It
is attractive to predict that the attenuating mutations in the M
gene segment, which seem to exert their effect through the M2
polypeptide (Table 1), might play a role in this phenomenon. On
the other hand, perhaps the predicted amino acid changes in the
vaccine M1 protein (Table 1) contribute to this relatively subtle
effect, possibly by altering the interaction between the matrix
protein and the nucleocapsid.
There was one particularly intriguing phenotype observed
among the reassortant strains. The recombinant virus that
contained the vaccine PB1-PA-NP genotype in the wt back-
ground (Table 6, virus 14) unexpectedly exhibited wt plaque
forming efficiency at 39 °C and was only partially attenuated.
This was unexpected because related viruses containing just two
of the three vaccine genes (PB1–NP or PA–NP; Table 6, viruses
9 and 10) were temperature-sensitive and attenuated. Additional
studies will be required to sort out this curious constellation
effect, but perhaps, in this particular reassortant strain, the
polymerase complex (Area et al., 2004; Biswas et al., 1998;
Biswas and Nayak, 1996; Gastaminza et al., 2003; Gonzalez
and Ortin, 1999; Gonzalez et al., 1996; Martin-Benito et al.,
2001; Mena et al., 1999; Poole et al., 2004) derived some
positive benefit from the fact that PB1 and PA both originated
from the same virus. Conceivably, this enhanced the stability or
activity of the PB1–PA complex enabling it to function more
effectively as a polymerase component, and this partially
suppressed the negative consequences of encoding several
vaccine proteins. Under these circumstances, this might have
allowed the properties of wt PB2 to dominate resulting in a wt-
like polymerase complex.
Materials and methods
Cell culture and virology
Madin–Darby canine kidney (MDCK) cells and COS-7 cells
were maintained in minimal essential medium (MEM) or
Dulbecco's Modification of Eagles Medium (DMEM), respec-
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cells were maintained at 37 °C in 5% CO2.
The wt isolate of A/Sydney/5/97 originated from the Centers
for Disease Control and Prevention, and was obtained from the
Vaccine Development Department at Wyeth. Wyeth and
Medimmune coproduced the A/Sydney/5/97 LAIV strain
(subtype H3N2) used for these studies (Buonagurio et al.,
2006). Both viruses were propagated in the allantoic cavity of
9-day old embryonated chicken eggs (Charles River SPAFAS,
Inc.), which were inoculated with approximately 103 plaque-
forming units (PFU) and incubated for 48–52 h at 33 °C. The
allantoic fluid from infected eggs was harvested, pooled, and
then clarified by centrifugation for 15 min at 500×g. Virus
stocks were stabilized by addition of 1/10 volume of 10×
Sucrose–Phosphate–Glutamate buffer (1× SPG: 0.22 M
sucrose, 7.1 mM K2HPO4, 3.8 mM KH2PO4, 4.9 mM glutamic
acid) before storage at −80 °C. Viruses were subjected to
genomic consensus sequence analysis as described previously
(Buonagurio et al., 2006).
Influenza virus titers were determined by plaque assay.
Nearly confluent MDCK cell monolayers cultured in 12-well
plates were prepared for infection by aspirating the medium and
washing twice with PBS. Virus was serially diluted in PBS
supplemented with 0.3% bovine serum albumin (BSA) before
the monolayers were infected with 0.1 ml of inoculum for 1 h at
33 °C, at which time 2 ml of agar overlay was added to each
well and allowed to solidify at room temperature. The overlay
was composed of MEM supplemented with 0.5 μg per ml
trypsin-TPCK (Worthington Biochemicals, Inc.), MEM-non-
essential amino acids, sodium pyruvate, penicillin, streptomy-
cin, 0.3% BSA, and 0.6% agar (Oxoid, LTD). The infected cells
were incubated for 3 days at 33 °C before the overlay was
removed and plaques were visualized by staining the monolayer
(0.1% crystal violet, 32% ethanol).
Recombinant DNA and influenza virus reverse-genetics
Plasmid DNAs required for recombinant influenza virus
rescue (Neumann et al., 1999) were prepared with standard
molecular cloning procedures (Ausubel et al., 1987). Influenza
virus genomic RNA was purified from wt or vaccine virus
stocks by the guanidinium thiocyanate–phenol–chloroform
extraction method (Chomczynski and Sacchi, 1987) performed
with Trizol reagent (Invitrogen). Viral cDNAs spanning
complete gene segments were synthesized by reverse transcrip-
tion and PCR amplification (RT/PCR) conducted with reagents
in the one-step Titan amplification kit (Roche Molecular). The
amplified DNAs subsequently were cloned into the pHH21
expression vector to allow synthesis of negative-sense genomic
RNA transcripts from a RNA polymerase I transcription unit
after transfection of eukaryotic cells (Neumann et al., 1994,
1999) (provided by Y. Kawaoka, University of Wisconsin-
Madison). The HA and NA gene segments were cloned only
from the A/Sydney/5/97 vaccine virus because they encode
polypeptides that are identical to wt (Buonagurio et al., 2006).
Both wt and vaccine virus PB2, PB1, PA, and NP coding
sequences were cloned into an RNA polymerase II expressionvector controlled by the CMV promoter (pCI-Neo, Promega).
These plasmids were used to express the viral RNA polymerase
subunits and the nucleocapsid protein in transfected cells during
virus rescue (Neumann et al., 1999). Plasmid DNA nucleotide
sequences were verified by automated cycle-sequencing
(Buonagurio et al., 2006) using Big Dye Terminator Mix v3.1
(Applied Biosystems).
Recombinant influenza virus was rescued as described earlier
(Neumann et al., 1999) except that COS-7 cells were used rather
then 293T cells. Briefly, the cells were grown in six well plates
until the monolayers were approximately 70% confluent, at
which time cells were transfected with 8 plasmids specifying the
desired wt or vaccine virus genome segments, and four plasmids
encoding the requisite trans-acting polypeptides. DNAs were
prepared for transfection by combining 2 μg of each plasmid
(24 μg total DNA) in 100 μl of serum-free OptiMEM-I
(Invitrogen). Then, 48 μl of transfection reagent (Trans IT LT-
1, Panvera) was diluted in 100 μl Opti-MEM I before it was
added to the DNA solution and the mixture was incubated at
room temperature for 45min. The total volume of the transfection
mixture subsequently was adjusted to 1.0 ml with serum-free
OptiMEM-I and transferred to the COS-7 cell monolayers from
which the culture medium had been removed. The cells were
incubated for 20–24 h at 33 °C (5% CO2), at which time the
transfection medium was replaced by OptiMEM-I containing
0.3% BSA and 0.01% FBS. Seventy-two hours post transfection,
the medium containing rescued virus was transferred to a
confluent MDCK cell monolayer and allowed to absorb for 2 h.
Subsequently, the medium was replaced with OptiMEM-I
supplemented with 0.3% BSA and 0.5 μg per ml trypsin. The
cells were incubated at 33 °C until cytopathic effect was evident,
at which time 100 μl of the supernatant was transferred to a fresh
MDCK monolayer to amplify the rescued virus. Virus harvested
in the medium supernatant was quantified by plaque assay on
MDCK cells and later amplified in 9-day old embryonated eggs,
as described above. Reassortant genotypes were verified by
partial genomic sequencing of all gene segments, or in some
cases by complete genome sequence determination.
Determination of virus phenotype
Parallel plaque assays (see above) conducted with MDCK
monolayers incubated at 33 °C and 39 °C were performed to
assess the ts phenotype. The efficiency of plaquing (EOP) value
was determined using the following formula: Log10(virus titer at
33 °C)−Log10(virus titer at 39 °C). Viruses were considered ts
if EOP values were equal to or greater than 2.0.
The att phenotype was evaluated after intranasal inoculation
of ferrets with recombinant influenza viruses. All animal care
and experimental procedures conformed to guidelines estab-
lished by the Institutional Animal Care and Use Committee, and
the facilities were approved by the American Association for
Accreditation and Laboratory Animal Care. Ferrets were
obtained from Marshall (North Rose, NY) or Triple-F Farms
(Sayre, Pennsylvania) and used for virus challenge at 7 weeks of
age. Males were supplied castrated and all animals were
vaccinated against canine distemper by the vendor. To confirm
286 C.L. Parks et al. / Virology 367 (2007) 275–287that ferrets used in virus challenge studies were seronegative,
animals were housed separately from the general population
and serum samples were drawn 1 week prior to shipment.
Serum samples were screened routinely for reactivity to A/
Sydney/5/97 (H3N2) with a standard hemagglutination inhi-
bition (HAI) assay (WHO, 2002). Periodically, serum samples
also were tested for antibodies reactive against both A/Sydney/
5/97 and A/New Caledonia/20/99 (H1N1) if an influenza
outbreak was suspected in the animal colony. To prepare
serum for analysis, nonspecific inhibitors of hemagglutination
were minimized by treating the serum with Receptor Destroy-
ing Enzyme (Denka Seika Co., LTD) at a 1:4 ratio for 18–20 h
at 37 °C. The enzyme and serum complement were inactivated
subsequently by incubation at 56 °C for 30 min. The serum
was then incubated with a 1/5th volume of a 10% suspension
of chicken red blood cells (RBC), which were removed
afterward by centrifugation. The treated serum then was used
to prepare a two-fold dilution series from which 25 μl was
mixed with 4 hemagglutinin units of virus in 96-well, round-
bottom plates. Antibody binding was conducted for 30 min at
room temperature before 50 μl of a 0.5% RBC suspension was
added to each well. The plates were incubated for 45 to 90 min
at 4 °C before the HAI titer was reported as the reciprocal
value of the last serum dilution that completely inhibited
hemagglutination.
Routinely, groups of 4–5 seronegative animals, composed of
both males and females, were inoculated to test each re-
combinant or control virus. Virus was prepared for ferret
infection by rapidly thawing frozen stocks in a 33 °C water bath
before temporary storage on ice. Each 0.2 ml dose was
formulated to contain 7.0 Log10 PFU of virus and placed in a
tuberculin syringe. Virus was administered to anesthetized
animals to prevent sneezing and to ensure uptake of the full virus
inoculum. Anesthesia was administered by first placing the
ferrets in a chamber receiving 1 l of oxygen containing 5%
isoflurane per minute, and was maintained with 1 l of oxygen
containing 1–2% isoflurane per minute. The tuberculin syringe
was used to administer 0.1 ml of virus formulation per nostril.
Animals generally woke from anesthesia within 10 min. Ferrets
subsequently were examined daily to identify distressed
animals, but no animals died prior to the scheduled end of the
experiment on day 3 following virus infection. Ferrets were
sacrificed by intraperitoneal administration of sodium pento-
barbital (100 mg/kg) before harvesting lung tissue and the nasal
turbinates. The lower lobe of the left lung was harvested first to
minimize the possibility that nasal turbinate extraction might
contaminate the lung with virus from the upper airways.
Extracted lung tissue was weighed then immersed in sufficient
ice-cold PBS/SPG (PBS adjusted to 1× SPG) to prepare a 10%
tissue extract by homogenization (90 s, 8–12,000 rpm, 4 °C)
with an Omni Homogenizer (Omni International). Harvested
nasal turbinates were placed in 2 ml ice cold PBS/SPG and
homogenized 15–30 s with a hand-held mini-homogenizer
(Kimble/Kontes Pellet Pestle Mixer). Both lung and nasal
turbinate extracts were clarified by centrifugation (500×g,
15 min, 4 °C) prior to flash freezing in 0.4 ml aliquots that
were stored at −70 °C.Acknowledgments
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